GO
Loading...

Merck & Co Inc

More

  • Merck CEO: Biotech valuations reflect optimism  Monday, 8 Dec 2014 | 10:17 AM ET

    Merck agreed to acquire Cubist Pharmaceuticals in a $9.5 billion deal. CNBC's Meg Tirrell discusses the price of the deal and patent challenges Merck may face.

  • NEW YORK, Dec 8- U.S. stocks dipped on Monday, after soft data in China and Japan raised global growth concerns, while a further drop in oil prices weighed on energy shares. Data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.

  • Merck CEO: Examining wide range of opportunities  Monday, 8 Dec 2014 | 9:37 AM ET

    CNBC's Meg Tirrell provides the latest details on Merck's acquisition of Cubist Pharmaceuticals.

  • NEW YORK, Dec 8- U.S. stocks were poised for a lower open on Monday, putting the S&P 500 on track to pull back from its latest record high, as soft data in China and Japan kindled global growth concerns. Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in...

  • Merck-Cubist deal about 'superbugs'  Monday, 8 Dec 2014 | 9:09 AM ET

    CNBC's David Faber and Jim Cramer discuss Merck's acquisition of Cubist Pharmaceuticals for $8.4 billion in cash plus $1.1 billion in debt.

  • Merck buys Cubist for $102 per share  Monday, 8 Dec 2014 | 8:28 AM ET

    Barbara Ryan, FTI Consulting managing director, breaks down the details on the merger.

  • NEW YORK, Dec 8- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from its latest record high, as soft data in China and Japan kindled global growth concerns. *Economic data showed China's exports rose at a slower than expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third...

  • Early movers: CBST, MRK, EBAY, SBUX, INFY & more Monday, 8 Dec 2014 | 7:52 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures fall after soft China, Japan data Monday, 8 Dec 2014 | 7:37 AM ET

    NEW YORK, Dec 8- U.S. stock index futures dipped on Monday, indicating the S&P 500 may retreat from a record high, as soft data in China and Japan stoked global growth concerns. *Merck& Co Inc said it would buy Cubist Pharmaceuticals Inc in a deal valued at $9.5 billion. *European shares were lower after the data from China and Japan.

  • Merck to buy Cubist in $9.5 billion deal  Monday, 8 Dec 2014 | 7:01 AM ET

    CNBC's Meg Tirrell reports on Merck's plans to acquire Cubist.

  • Dec 6- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday. Margaret Shipp, co-lead investigator of the Checkmate-039 study from Dana-Farber Cancer Institute in Boston. The results were being...

  • Dec 6- Merck& Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer...

  • Merck in talks to buy Cubist for over $8B Friday, 5 Dec 2014 | 11:51 PM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Drug giant Merck is in talks to acquire antibiotics maker Cubist for about $102 a share in cash, according to people familiar with the matter.

  • Ebola booster vaccine starts first trials in Oxford Thursday, 4 Dec 2014 | 4:25 AM ET

    LONDON, Dec 4- Scientists at Oxford University have launched the first clinical tests of a new Ebola vaccine approach, using a booster developed by Denmark's Bavarian Nordic that may improve the effects of a shot from GlaxoSmithKline. Thirty healthy volunteers in Britain who have already received the experimental Ebola vaccine being developed by GSK and the...

  • Dec 2- Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a small early-stage study. Brain swelling has been a recurrent issue with experimental anti-amyloid Alzheimer's drugs,...

  • Back for more: Will Pfizer top its AstraZeneca bid? Wednesday, 26 Nov 2014 | 3:34 AM ET
    Viagra made by Pfizer and Nexium made by AstraZeneca.

    Pfizer’s $110 billion bid for AstraZeneca was one of the biggest business stories of 2014 – so could a new bid be one of the biggest stories in 2015?

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...

  • Nov 24- Merck& Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine. The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug. The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015..

  • Dow, S&P close at records; Intel up 4% Thursday, 20 Nov 2014 | 4:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed at highs after encouraging domestic data alleviated concerns over continued signs of slowing growth in Europe and China.

  • Stocks little moved; S&P 500 at record-high close Monday, 17 Nov 2014 | 4:00 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks fell Monday after data had Japan unexpectedly falling into a recession.